Bacillary Dysentery (Shigellosis) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Bacillary Dysentery (Shigellosis) – Pipeline Review, H1 2017’, provides an overview of the Bacillary Dysentery (Shigellosis) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bacillary Dysentery (Shigellosis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bacillary Dysentery (Shigellosis) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Bacillary Dysentery (Shigellosis)

The report reviews pipeline therapeutics for Bacillary Dysentery (Shigellosis) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Bacillary Dysentery (Shigellosis) therapeutics and enlists all their major and minor projects

The report assesses Bacillary Dysentery (Shigellosis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Bacillary Dysentery (Shigellosis)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Bacillary Dysentery (Shigellosis)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Bacillary Dysentery (Shigellosis) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Akthelia Pharmaceuticals Ltd

GlaxoSmithKline Plc

Microbiotix Inc

Protein Potential LLC

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Bacillary Dysentery (Shigellosis) - Overview

Bacillary Dysentery (Shigellosis) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Bacillary Dysentery (Shigellosis) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bacillary Dysentery (Shigellosis) - Companies Involved in Therapeutics Development

Akthelia Pharmaceuticals Ltd

GlaxoSmithKline Plc

Microbiotix Inc

Protein Potential LLC

Bacillary Dysentery (Shigellosis) - Drug Profiles

(shigella + typhoid) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AKT-10081 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GVXNSD-133 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KKL-35 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SC-599 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SE-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SF2a-TT15 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

shigella [serotype 2a] (whole cell) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

shigella [strain 53G] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

shigella vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

shigella vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Shigetec - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate IL-10 for Bacterial Infections and Crohn's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WRSs-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WRSs-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bacillary Dysentery (Shigellosis) - Dormant Projects

Bacillary Dysentery (Shigellosis) - Discontinued Products

Bacillary Dysentery (Shigellosis) - Product Development Milestones

Featured News & Press Releases

Jul 29, 2013: GlycoVaxyn Secures CHF

5.1 Million Strategic Translation Award From the Wellcome Trust to Finance Clinical Development of Shigella Vaccine

Feb 20, 2013: NIH-Funded Researchers Begin Trial of Shigella Vaccine Candidates

Oct 08, 2010: GlycoVaxyn Phase I Clinical Study Shows Positive Data With Shigella Dysenteriae Vaccine Candidate Against Severe Diarrheal Disease

Feb 23, 2010: GlycoVaxyn Initiates Phase I Clinical Study with Bioconjugate Vaccine

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Bacillary Dysentery (Shigellosis), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Bacillary Dysentery (Shigellosis) – Pipeline by Akthelia Pharmaceuticals Ltd, H1 2017

Bacillary Dysentery (Shigellosis) – Pipeline by GlaxoSmithKline Plc, H1 2017

Bacillary Dysentery (Shigellosis) – Pipeline by Microbiotix Inc, H1 2017

Bacillary Dysentery (Shigellosis) – Pipeline by Protein Potential LLC, H1 2017

Bacillary Dysentery (Shigellosis) – Dormant Projects, H1 2017

Bacillary Dysentery (Shigellosis) – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Bacillary Dysentery (Shigellosis), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports